Disease · MONDO_0006608

seborrheic dermatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. seborrheic dermatitis. Diseases, record MONDO_0006608. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006608

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: seborrheic dermatitis; Open Targets
Open Targets ID: MONDO_0006608; Open Targets
Other names: cradle Cap, seborrhea, seborrheic dermatitis (disease), seborrheic eczema, seborrhoea, seborrhoeic eczema, skin seborrheic; Open Targets
Disease Ontology: DOID:8741; Disease Ontology
MeSH: D012628; MeSH
NCI Thesaurus: C111888; NCI Thesaurus
Highest stage of its drugs: Approval, for 13 of its 29 drugs, from DailyMed; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
KETOCONAZOLE	CHEMBL157101	Small molecule	Approval	DailyMed	23	4	4	Drugs and targets
SALICYLIC ACID	CHEMBL424	Small molecule	Approval	DailyMed	22	0	0	Drugs and targets
SELENIUM SULFIDE	CHEMBL1200680	Small molecule	Approval	DailyMed	8	0	0	Drugs and targets
COAL TAR	CHEMBL2108232		Approval	DailyMed	7	0	0	Drugs and targets
CICLOPIROX	CHEMBL1413	Small molecule	Approval	DailyMed	5	0	0	Drugs and targets
HYDROCORTISONE BUTYRATE	CHEMBL1683	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	1	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Tyrosine-protein kinase JAK3	1	Tyrosine-protein kinase JAK3 inhibitor	Phase 2	https://conductscience.org/library/genes/3718	Drugs and targets
PDE4A	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5144	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	1	Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 1	https://conductscience.org/library/genes/6616	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00703846	STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%	Phase 4	498	2012-02-23	Dermatitis, Seborrheic	KETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04973228	Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)	Phase 3	457	2024-03-12	Seborrheic Dermatitis	ROFLUMILAST	Its record names the disease	ClinicalTrials.gov
NCT04445987	Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis	Phase 2	408	2024-06-11	Seborrheic Dermatitis	ROFLUMILAST	Its record names the disease	ClinicalTrials.gov
NCT00862654	Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis	Phase 3	326	2011-08-12	Scalp Seborrheic Dermatitis	CLOBETASOL PROPIONATE, KETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04091646	Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis	Phase 2	226	2023-07-03	Seborrheic Dermatitis	ROFLUMILAST	Its record names the disease	ClinicalTrials.gov
NCT00403559	A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis	Phase 2	113	2022-03-14	Seborrheic Dermatitis	KETOCONAZOLE, PIMECROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03830177	Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult	Phase 1/2	77	2025-02-24	Dermatitis, Seborrheic, Dry Skin; Eczema	HONEY	Its record names the disease	ClinicalTrials.gov
NCT05787860	Ruxolitinib in Seborrheic Dermatitis	Phase 2	45	2025-05-06	Seborrheic Dermatitis	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT01203189	Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo	Not applicable	23	2017-11-06	Seborrheic Dermatitis	KETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01011621	Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis	Phase 3	170		Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis	BETAMETHASONE VALERATE, PREDNISOLONE ACETATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Roflumilast Foam 0.3% vs Vehicle Foam: deaths from any cause	0 of 304	0 of 153	457	NCT04973228	Trial comparisons
Roflumilast Foam 0.3% vs Vehicle Foam: serious adverse events	1 of 304	0 of 153	457	NCT04973228	Trial comparisons
Roflumilast Foam 0.3% vs Vehicle Foam: deaths from any cause	0 of 154	0 of 72	226	NCT04091646	Trial comparisons
Roflumilast Foam 0.3% vs Vehicle Foam: serious adverse events	0 of 154	0 of 72	226	NCT04091646	Trial comparisons
Roflumilast Foam 0.3% vs Vehicle Foam: Achievement of Investigator Global Assessment (IGA) Success at Week 8	104 of 141	27 of 66	207	NCT04091646	Trial comparisons
Elidel Cream (Pimecrolimus) vs Ketoconazole Cream (Nizoral): Key Secondary Efficacy Will be the % of Patients With Facial Clearance	56 of 56	56 of 56	112	NCT00403559	Trial comparisons
Elidel Cream vs Ketoconazole Cream: deaths from any cause	0 of 56	0 of 56	112	NCT00403559	Trial comparisons
Elidel Cream vs Ketoconazole Cream: serious adverse events	0 of 56	0 of 56	112	NCT00403559	Trial comparisons
Adults vs Children: deaths from any cause	0 of 35	0 of 42	77	NCT03830177	Trial comparisons
Adults vs Children: serious adverse events	0 of 35	0 of 42	77	NCT03830177	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41175336	DERIVED	1	PubMed
37133856	DERIVED	1	PubMed
23377341	DERIVED	1	PubMed
21707573	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006608

GET https://conductscience.org/api/diseases/v1/MONDO_0006608/drugs?page=2

API reference For AI assistants